Optimizing Dermatology Express Scripts Integration for Prior Authorization

Achieving seamless dermatology Express Scripts integration is critical for managing the high volume of prior authorizations for specialty drugs and procedures. Klivira automates this complex workflow, ensuring timely approvals for your patients.

Revenue cycle leaders and prior authorization coordinators in dermatology face unique challenges when navigating PBM requirements, especially with a major player like Express Scripts (an Evernorth pharmacy). The intricate policies for biologics, specialty topicals, and surgical procedures demand precise documentation and efficient submission. Klivira’s platform is engineered to address these specific pain points, transforming a historically manual process into an automated, data-driven workflow.

The Specifics of Express Scripts PA in Dermatology

Dermatology prior authorizations with Express Scripts often revolve around high-cost medications and specific procedures. These include biologics for conditions such as psoriasis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi), atopic dermatitis, and hidradenitis suppurativa, as well as specialty topicals and Mohs micrographic surgery. Klivira's integration is designed to manage the distinct requirements of these categories, from initial submission to periodic re-authorizations.

Common Dermatology PA Triggers with Express Scripts

Biologics for psoriasis and psoriatic arthritis (e.g., TNF, IL-17, IL-23 inhibitors, oral targeted therapies)
Biologics for atopic dermatitis (e.g., dupilumab, tralokinumab, lebrikizumab, oral JAK inhibitors)
Hidradenitis suppurativa biologics (e.g., adalimumab, secukinumab)
Mohs micrographic surgery for non-melanoma skin cancers
Advanced skin cancer treatments (e.g., immunotherapy, targeted therapy for melanoma)
Phototherapy, particularly for home-based administration

Meeting Express Scripts Documentation Requirements for Dermatology

Express Scripts, like other PBMs, requires specific clinical documentation to approve dermatology PAs. These often align with AAD Clinical Guidelines and NCCN for skin cancers. Key data points include disease severity scores (e.g., PASI, BSA, EASI, SCORAD), evidence of failed prior topical or systemic therapies, TB and hepatitis screenings for biologics, and adherence to Appropriate Use Criteria (AUC) for procedures like Mohs surgery. Klivira helps structure and validate these requirements before submission.

Addressing Common Dermatology PA Denial Reasons

Failure to document step therapy compliance for psoriasis biologics (e.g., trial of conventional systemic therapy)
Lack of documentation for biosimilar substitution where applicable for TNF inhibitors
Mohs AUC mismatch, where site or tumor type does not meet indications
Insufficient disease severity documentation (missing PASI, EASI, BSA scores)
Gaps in pre-biologic screenings (e.g., TB, hepatitis)

Klivira's Technical Approach to Express Scripts Integration

Klivira integrates directly with your EMR and connects to Express Scripts through various channels. This includes leveraging X12 278 transactions for medical benefit PAs, NCPDP SCRIPT for pharmacy benefit PAs, and direct portal automation where necessary. Our platform utilizes AAD-guideline-aware step-therapy logic, AUC validation for Mohs surgery, and a workflow for periodic re-authorization of chronic biologic treatments, ensuring that submissions are complete and accurate. We also facilitate the critical distinction between medical and pharmacy benefit routing, a common workflow constraint in dermatology.

Streamlining EMR and Payer Touchpoints for Dermatology Practices

Effective dermatology Express Scripts integration requires seamless interaction between your EMR and the payer. Klivira minimizes manual data entry by extracting relevant clinical data from your EMR, populating Express Scripts' specific forms and fields. This includes data points from clinical templates for biologics, procedure orders for Mohs surgery, and patient history. Our system is designed to handle the nuances of both medical and pharmacy benefit drug routing, reducing administrative burden and accelerating time to therapy for patients.

Frequently asked questions

How does Klivira handle the distinction between medical and pharmacy benefit PAs for Express Scripts in dermatology?

Klivira's platform is configured to identify whether a dermatology medication (e.g., a self-injectable biologic versus an infused biologic) falls under the medical or pharmacy benefit. It then routes the prior authorization request appropriately, leveraging NCPDP SCRIPT for pharmacy benefit PAs and X12 278 for medical benefit PAs, or utilizing direct portal automation.

Can Klivira help with re-authorizations for chronic dermatology conditions managed by Express Scripts?

Yes, Klivira supports the periodic re-authorization workflow common for chronic dermatology conditions requiring biologics. Our system tracks approval expiry dates and proactively initiates the re-authorization process, ensuring continuous coverage and minimizing treatment interruptions for patients.

Does Klivira integrate with my EMR to pull clinical data for Express Scripts dermatology PAs?

Klivira integrates with leading EMRs via industry standards like SMART on FHIR, enabling the extraction of relevant clinical data. This data, such as diagnosis codes, lab results, and documentation of prior therapies, is then used to auto-populate Express Scripts' prior authorization forms, reducing manual effort and improving accuracy.

How does Klivira address Express Scripts' step therapy requirements for dermatology biologics?

Klivira incorporates AAD-guideline-aware step-therapy logic. The system identifies if required prior topical or conventional systemic therapies have been documented in the patient's EMR. If not, it flags these requirements, helping ensure that submissions to Express Scripts are compliant with their step therapy policies.